Loading...
Market
How will Eisai and Biogen's stock prices change by July 31, 2024, following the CHMP decision?
2
Resolution / Starting Odds
Increase by more than 5% • 25%
Decrease by more than 5% • 25%
Fluctuate within ±5% • 25%
No significant change • 25%
Public stock market data
Story
CHMP Recommends EU Rejection of Eisai and Biogen's Alzheimer's Drug Leqembi
Jul 26, 2024, 11:19 AM
On July 26, 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on lecanemab, also known as Leqembi, an Alzheimer's therapy developed by Eisai and Biogen, recommending its rejection in the European Union. This decision diverges from the stance of U.S. regulators, who have approved the medicine. The rejection is a significant setback for Eisai and Biogen, who were seeking to expand sales of the drug in Europe.
View original story
Similar markets
Higher than competitors • 25%
On par with competitors • 25%
Lower than competitors • 25%
Significantly lower than competitors • 25%
Increase by more than 5% • 25%
Increase by 0% to 5% • 25%
Decrease by 0% to 5% • 25%
Decrease by more than 5% • 25%
Increases by more than 10% • 25%
Increases by 5-10% • 25%
Changes by less than 5% • 25%
Decreases • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No significant change or decrease • 25%
Increase over 20% • 25%
Increase 0-20% • 25%
No change • 25%
Decrease • 25%
Alzheimer's drug • 25%
Multiple Sclerosis drug • 25%
Neuromuscular drug • 25%
Other • 25%